The role of an alginate suspension on pepsin and bile acids - Key aggressors in the gastric refluxate. Does this have implications for the treatment of gastro-oesophageal reflux disease?

Journal of Pharmacy and Pharmacology

Volumn 61, Issue 8, 2009, Pages 1021-1028

  Strugala, Vicki ^a   Avis, Jeanine ^a   Jolliffe, Ian G ^b   Johnstone, Lesley M ^b   Dettmar, Peter W ^a  

^a The Deep Business Centre   (United Kingdom)

^b RECKITT BENCKISER   (United Kingdom)

Author keywords

Alginate; Bile acids; Formulation; Gastro oesophageal reflux; Oesophagus; Pepsin

Indexed keywords

ALGINIC ACID; BILE ACID; COLLAGEN; GAVISCON; GAVISCON ADVANCE; PEPSIN A; UNCLASSIFIED DRUG; BICARBONATE; GLUCURONIC ACID; HEXURONIC ACID; POTASSIUM BICARBONATE; POTASSIUM DERIVATIVE;

ARTICLE; COLORIMETRY; DIFFUSION; DRUG EFFECT; DRUG FORMULATION; ENZYME ACTIVITY; ENZYME INHIBITION; ESOPHAGUS INJURY; GASTROESOPHAGEAL REFLUX; HUMAN; IN VITRO STUDY; STOMACH JUICE; ANIMAL; BIOLOGICAL MODEL; DOSE RESPONSE; DRUG COMBINATION; ESOPHAGUS; METABOLISM; METHODOLOGY; PATHOLOGY; SWINE;

ALGINATES; ANIMALS; BICARBONATES; BILE ACIDS AND SALTS; COLORIMETRY; DIFFUSION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG COMBINATIONS; ESOPHAGUS; GASTROESOPHAGEAL REFLUX; GLUCURONIC ACID; HEXURONIC ACIDS; HUMANS; MODELS, BIOLOGICAL; PEPSIN A; POTASSIUM COMPOUNDS; SWINE;

EID: 85047685290     PISSN: 00223573     EISSN: None     Source Type: Journal    
DOI: 10.1211/jpp.61.08.0005     Document Type: Article

References (31)

1. Chatfield S. A comparison of the efficacy of the alginate preparation, Gaviscon Advance, with placebo in the treatment of gastro-oesophageal reflux disease. Curr Med Res Opin 1999; 15: 152-159.
2. Dettmar PW et al. The suppression of gastro-oesophageal reflux by alginates. Int J Clin Pract 2007; 61: 1654-1662.
3. Dettmar PW et al. Rapid onset of effect of sodium alginate on gastro-oesophageal reflux compared with ranitidine and ome-prazole, and relationship between symptoms and reflux episodes. Int J Clin Pract 2006; 60: 275-283.
4. Hampson FC et al. Alginate rafts and their characterisation. Int J Pharm 2005; 294: 137-147.
5. Gotley DC et al. Composition of gastro-oesophageal refluxate. Gut 1991; 32: 1093-1099.
6. Koek GH et al. Mechansims underlying duodeno-gastric reflux in man. Neurogastoenterol Motil 2005; 17: 191-199.
7. Ten Kate RW et al. Effect of high dose omeprazole on gastric pepsin secretion and serum pepsinogen levels in man. Eur J Clin Pharmacol 1988; 35: 173-176.
8. Goldberg HI et al. Role of acid and pepsin in acute experimental esophagitis. Gastroenterology 1969; 56: 223-230.
9. Salo JA et al. Morphological alterations in experimental esophagitis. Light microscopic and scanning and transmission electron microscopic study. Dig Dis Sci 1983; 28: 440-448.
10. Johnson LF, Harmon JW. Experimental esophagitis in a rabbit model. Clinical relevance. J Clin Gastroenterol 1986; 8: 26-44.
11. Tobey NA et al. The role of pepsin in acid injury to esophageal epithelium. Am J Gastroenterol 2001; 96: 3062-3070.
12. Johnston N et al. Activity/stability of human pepsin: implications for reflux attributed laryngeal disease. Laryngoscope 2007; 117: 1036-1039.
13. Kauer WK et al. Composition and concentration of bile acid reflux into the esophagus of patients with gastroesophageal reflux disease. Surgery 1997; 122: 874-881.
14. Nehra D et al. Toxic bile acids in gastro-oesophageal reflux disease: influence of gastric acidity. Gut 1999; 44: 598-602.
15. Roman S et al. Downregulation of p63 upon exposure to bile salts and acid in normal and cancer esophageal cells in culture. Am J Physiol (GI Liver Physiol) 2007; 293: G45-G53.
16. Zhang T et al. A rat surgical model of esophageal metaplasia and adenocarcinoma-induced by mixed reflux of gastric acid and duodenal contents. Dig Dis Sci 2007; 52: 3202-3208.
17. Boni L et al. Free radical production in the oesophago-gastro- duodenal mucosa in response to acid and bile. Dis Esophagus 2006; 19: 99-104.
18. Dvorak K et al. Bile acids in combination with low pH induce oxidative stress and oxidative DNA damage: relevance to the pathogenesis of Barrett's oesophagus. Gut 2007; 56: 763-771.
19. Fein M et al. Carcinogenesis in reflux disease - in search for bile-specific effects. Microsurgery 2007; 27: 647-650.
20. Jenkins GJ et al. The bile acid deoxycholic acid has a non-linear dose response for DNA damage and possibly NF-kB activation in oesophageal cells, with a mechanism of action involving ROS. Mutagenesis 2008; 23: 399-405.
21. Tselepis C et al. Upregulation of the oncogene c-myc in Barrett's adenocarcinoma: induction of c-myc by acidified bile acid in vitro. Gut 2003; 52: 174-180.
22. Vela MF et al. Simultaneous intraesophageal impedance and pH measurement of acid and nonacid gastroesophageal reflux: effect of omeprazole. Gastroenterology 2001; 120: 1599-1606.
23. Tamhankar AP et al. Omeprazole does not reduce gastroesophageal reflux: new insights using multichannel intraluminal impedance technology. J Gastrointest Surg 2004; 8: 888-896.
24. Hemmink GJM et al. Esopageal pH-impedance monitoring in patients with therapy-resistant reflux symptoms: 'on' or 'off' proton pump inhibitor? Am J Gastroenterol 2008; 103: 2446-2453.
25. Hutton DA et al. Separation of pepsin in human gastric juice: analysis of proteolytic and mucolytic activity. Biochem Soc Trans 1986; 14: 735.
26. Strugala V et al. Inhibition of pepsin activity by alginates in vitro and the effect of epimerization. Int J Pharm 2005; 304: 40-50.
27. Will PC et al. Quantification of pepsin A activity in canine and rat gastric juice with the chromogenic substrate Azocoll. Clin Chem 1984; 30: 707-711.
28. Foster SNE et al. Interaction of polyacrylates with porcine pepsin and the gastric mucus barrier: a mechanism for mucosal protection. Clinical Science 1994; 87: 719-726.
29. Allen A et al. Pepsins. In: Wallace JL, ed. Endogenous Mediators of Gastrointestinal Disease. CRC Press, 1990: 53-69.
30. Rhee PL et al. Measuring esophageal distension by high-frequency intraluminal ultrasound probe. Am J Physiol (GI Liver Physiol) 2002; 283: G886-G892.
31. Sifrim D. Relevance of volume and proximal extent on gastro-esophageal reflux disease. Gut 2005; 54: 175-178.